atorvastatin has been researched along with Proteinuria in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, AR; Dunning, SC; Fine, DM; Grams, ME; Inker, LA; Nolin, TD; Sang, Y; Shin, JI; Surapaneni, A | 1 |
| de Zeeuw, D; Heerspink, HJL; Kroonen, MYAM; Stevens, J | 1 |
| de Fijter, JW; Dekker, FW; Dekkers, OM; Esmeijer, K; Hoogeveen, EK | 1 |
| Ababneh, MA; Al Demour, S; Alzoubi, KH; Hijjawi, TB; Rababa’h, AM | 1 |
| de Zeeuw, D; Heerspink, HJL; Idzerda, NMA; Parving, HH; Pena, MJ | 1 |
| Deng, T; Li, H; Li, Y; Tian, L; Zhao, P; Zhou, S | 1 |
| Anzalone, DA; Cain, VA; Cressman, MD; de Zeeuw, D; Heerspink, HJ; Molitoris, BA; Monyak, JT; Parving, HH; Remuzzi, G; Sowers, JR; Vidt, DG | 1 |
| Chen, J; Hu, YJ; Peng, DF; Tang, SY | 1 |
| An, C; An, F; Dong, Z; Liu, H; Wang, Y; Wu, Y; Zhang, M; Zhang, Y | 1 |
| Musella, F; Paneni, F; Perrone-Filardi, P; Savarese, G; Volpe, M | 1 |
| Baigorria, ST; Eynard, AR; Fiore, MC; García, NH; Juncos, LA; Juncos, LI; Martín, FL; Pasqualini, ME | 1 |
| Bianchi, S; Bigazzi, R; Caiazza, A; Campese, VM | 1 |
| Abud-Mendoza, C; Baranda, L; Cruz-Rizo, J; Cuevas-Orta, E; de la Fuente, H; González-Amaro, R | 1 |
| Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Gu, M; Liu, M; Wu, Y; Yin, C; Zhang, W; Zhu, P | 1 |
| Bayés, B; Blanco, S; Bonet, J; Lauzurica, R; Navarro-Muñoz, M; Romero, R | 1 |
| Jaimes, EA; Raij, L; Schuman, IH; Zhou, MS | 1 |
4 review(s) available for atorvastatin and Proteinuria
| Article | Year |
|---|---|
Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis.
Topics: Atorvastatin; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lovastatin; Network Meta-Analysis; Pravastatin; Proteinuria; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2019 |
Effects of rosuvastatin and atorvastatin on renal function: meta-analysis.
Topics: Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Proteinuria; PubMed; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2012 |
Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis.
Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
6 trial(s) available for atorvastatin and Proteinuria
| Article | Year |
|---|---|
Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Creatinine; Diabetes Complications; Female; Humans; Kidney Function Tests; Male; Middle Aged; Proteinuria; Renal Insufficiency, Chronic; Rosuvastatin Calcium | 2019 |
Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials.
Topics: Atorvastatin; Cholesterol; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Function Tests; Male; Middle Aged; Proteinuria; Rosuvastatin Calcium | 2019 |
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
Topics: Adult; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Creatinine; Diabetes Complications; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Fluorobenzenes; Heptanoic Acids; Humans; Kidney; Lipids; North America; Proteinuria; Pyrimidines; Pyrroles; Rosuvastatin Calcium; South America; Sulfonamides | 2015 |
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrroles | 2003 |
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Atorvastatin; Biomarkers; Blood Sedimentation; C-Reactive Protein; Child; Chloroquine; Dose-Response Relationship, Drug; Granulomatosis with Polyangiitis; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Middle Aged; Proteinuria; Pyrroles; Rheumatic Diseases; Rheumatic Fever; Simvastatin; Treatment Outcome | 2003 |
Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?
Topics: Adult; Aged; Atorvastatin; Blood Pressure; Cohort Studies; Dyslipidemias; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Proteinuria; Pyrroles; Transforming Growth Factor beta | 2007 |
8 other study(ies) available for atorvastatin and Proteinuria
| Article | Year |
|---|---|
Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria.
Topics: Atorvastatin; Hematuria; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proteinuria; Renal Insufficiency, Chronic; Rosuvastatin Calcium | 2022 |
The Nephroprotective Effect of N-Acetyl-L-Cysteine and Atorvastatin against Imipenem induced Nephrotoxicity.
Topics: Acetylcysteine; Animals; Antioxidants; Atorvastatin; Blood Urea Nitrogen; Creatinine; Glomerular Filtration Rate; Glycosuria; Imipenem; Kidney; Kidney Diseases; Male; Protective Agents; Proteinuria; Rats, Sprague-Dawley; Thiobarbituric Acid Reactive Substances; Urea | 2018 |
Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism.
Topics: Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Kidney; Lipoproteins, HDL; Lipoproteins, LDL; Male; Proteinuria; Pyrroles; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin; Transforming Growth Factor beta1 | 2014 |
Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
Topics: Angiotensin II; Animals; Atorvastatin; Benzazepines; C-Reactive Protein; Cardio-Renal Syndrome; Case-Control Studies; Drug Synergism; Heptanoic Acids; Lipids; Male; Natriuretic Peptide, Brain; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2015 |
Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency.
Topics: Animals; Atorvastatin; Blood Pressure; Creatinine; Diet; Fatty Acids, Unsaturated; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney; Male; Nephrectomy; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Sodium; Sodium Chloride, Dietary | 2012 |
The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol; Chronic Disease; Creatinine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerulonephritis; Heptanoic Acids; Humans; Insulin; Insulin, Long-Acting; Insulin, Regular, Human; Lipoproteins; Male; Middle Aged; Proteinuria; Pyrroles; Retrospective Studies; Serum Albumin; Serum Albumin, Human; Time Factors; Treatment Outcome | 2005 |
Protective effects of atorvastatin on chronic allograft nephropathy in rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chemokines; Chronic Disease; Cyclosporine; Cytokines; Drug Therapy, Combination; Extracellular Matrix Proteins; Fibrosis; Gene Expression; Graft Rejection; Heptanoic Acids; Immunosuppressive Agents; Kidney Transplantation; Male; Monocytes; Proteinuria; Pyrroles; Rats; Rats, Inbred F344; Rats, Inbred Lew; T-Lymphocytes; Transplantation, Homologous | 2007 |
Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability.
Topics: Animals; Atorvastatin; Biological Availability; Blood Pressure; Chemokine CCL2; Fibronectins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Failure, Chronic; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Proteinuria; Pyrroles; Rats; Rats, Inbred Dahl; RNA, Messenger; Scavenger Receptors, Class E; Transforming Growth Factor beta | 2008 |